Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. Nat Commun. 2018 03 23; 9(1):1219.
View in:
PubMed
subject areas
Adult
Adult
Aged
Aged
Aged, 80 and over
Aged, 80 and over
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols
Area Under Curve
Area Under Curve
Biomarkers, Tumor
Biomarkers, Tumor
Breast Neoplasms
Breast Neoplasms
Disease Progression
Disease Progression
Disease-Free Survival
Disease-Free Survival
DNA, Single-Stranded
DNA, Single-Stranded
Female
Female
Gene Expression Regulation, Neoplastic
Gene Expression Regulation, Neoplastic
Humans
Humans
Kaplan-Meier Estimate
Kaplan-Meier Estimate
Ligands
Ligands
Middle Aged
Middle Aged
Phenotype
Phenotype
Precision Medicine
Precision Medicine
SELEX Aptamer Technique
SELEX Aptamer Technique
Sequence Analysis, DNA
Sequence Analysis, DNA
Trastuzumab
Trastuzumab
Treatment Outcome
Treatment Outcome